Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Czaplinski

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Journal of Neurology|March 3, 2004
Immune mediated neuropathies--an update on therapeutic strategiesAdam Czaplinski, Andreas J Steck
British Journal of Neurosurgery|October 1, 2013
Extradural spinal cavernous malformation: a rare but important mimicTim Killeen, Adam Czaplinski, Evaldas Cesnulis
BMC Pharmacology & Toxicology|April 19, 2015
A Swiss real world best practice experience in three different clinical settings of the 6 hour fingolimod first dose observation procedureSimon P Ramseier, Serge Roth, Adam Czaplinski
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 21, 2008
Inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies: treatment updateAndreas J Steck, Adam Czaplinski, Susanne Renaud
Journal of Neurology|June 15, 2006
Amyotrophic lateral sclerosis: early predictors of prolonged survivalAdam Czaplinski, Albert A Yen, Stanley H Appel
Muscle & Nerve|September 13, 2006
Predictability of disease progression in amyotrophic lateral sclerosisAdam Czaplinski, Albert A Yen, Ericka P Simpson, et al.
Archives of Neurology|August 16, 2006
Slower disease progression and prolonged survival in contemporary patients with amyotrophic lateral sclerosis: is the natural history of amyotrophic lateral sclerosis changing?Adam Czaplinski, Albert A Yen, Ericka P Simpson, et al.
Heliyon|January 1, 2021
SwissTecLive: effectiveness and safety of dimethyl fumarate in the treatment of RRMS in the Swiss clinical practice settingChiara Zecca, Adam Czaplinski, Christophe Henny, et al.
Neurology|January 21, 2018
Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosisThomas Wehrum, Lena-Alexandra Beume, Oliver Stich, et al.
Frontiers in Neurology|October 27, 2018
Role of Family Planning in Women With Multiple Sclerosis in Switzerland: Results of the Women With Multiple Sclerosis Patient SurveyChristian P Kamm, Sarah Muehl, Dennis Mircsof, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Journal of Neurology|March 3, 2004
Immune mediated neuropathies--an update on therapeutic strategiesAdam Czaplinski, Andreas J Steck
British Journal of Neurosurgery|October 1, 2013
Extradural spinal cavernous malformation: a rare but important mimicTim Killeen, Adam Czaplinski, Evaldas Cesnulis
BMC Pharmacology & Toxicology|April 19, 2015
A Swiss real world best practice experience in three different clinical settings of the 6 hour fingolimod first dose observation procedureSimon P Ramseier, Serge Roth, Adam Czaplinski
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 21, 2008
Inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies: treatment updateAndreas J Steck, Adam Czaplinski, Susanne Renaud
Journal of Neurology|June 15, 2006
Amyotrophic lateral sclerosis: early predictors of prolonged survivalAdam Czaplinski, Albert A Yen, Stanley H Appel
Muscle & Nerve|September 13, 2006
Predictability of disease progression in amyotrophic lateral sclerosisAdam Czaplinski, Albert A Yen, Ericka P Simpson, et al.
Archives of Neurology|August 16, 2006
Slower disease progression and prolonged survival in contemporary patients with amyotrophic lateral sclerosis: is the natural history of amyotrophic lateral sclerosis changing?Adam Czaplinski, Albert A Yen, Ericka P Simpson, et al.
Heliyon|January 1, 2021
SwissTecLive: effectiveness and safety of dimethyl fumarate in the treatment of RRMS in the Swiss clinical practice settingChiara Zecca, Adam Czaplinski, Christophe Henny, et al.
Neurology|January 21, 2018
Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosisThomas Wehrum, Lena-Alexandra Beume, Oliver Stich, et al.
Frontiers in Neurology|October 27, 2018
Role of Family Planning in Women With Multiple Sclerosis in Switzerland: Results of the Women With Multiple Sclerosis Patient SurveyChristian P Kamm, Sarah Muehl, Dennis Mircsof, et al.
Pageof 2